These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 37304541)
1. Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial. Sano D; Oridate N Transl Cancer Res; 2023 May; 12(5):1363-1367. PubMed ID: 37304541 [No Abstract] [Full Text] [Related]
2. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226 [TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy. Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473 [TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. Poulose JV; Kainickal CT World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989 [TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis. She L; Tian K; Han J; Zuo W; Wang Z; Zhang N Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156 [TBL] [Abstract][Full Text] [Related]
6. Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan. Sano D; Tokuhisa M; Takahashi H; Hatano T; Nishimura G; Ichikawa Y; Oridate N Anticancer Res; 2022 Sep; 42(9):4477-4484. PubMed ID: 36039457 [TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ; Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740 [TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D; Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945 [TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888 [TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis. Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281 [TBL] [Abstract][Full Text] [Related]
13. The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus. Liu L; Xiang Z; Li Y; Guo W; Yang K; Wang J; Sun Z; Ren G; Zhang J; Sun M; Ran W; Huang G; Tang Z; Li L Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):619-628. PubMed ID: 36416313 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Balar AV; Castellano DE; Grivas P; Vaughn DJ; Powles T; Vuky J; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Necchi A; Petrylak DP; Plimack ER; Xu JZ; Imai K; Moreno BH; Bellmunt J; de Wit R; O'Donnell PH Ann Oncol; 2023 Mar; 34(3):289-299. PubMed ID: 36494006 [TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. Zhou K; Li Y; Liao W; Zhang M; Bai L; Li Q Oral Oncol; 2020 Aug; 107():104754. PubMed ID: 32428689 [TBL] [Abstract][Full Text] [Related]
16. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck. Saada-Bouzid E; Peyrade F; Guigay J Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146 [TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369 [No Abstract] [Full Text] [Related]
19. Immunotherapy in head and neck cancer: aiming at EXTREME precision. Szturz P; Vermorken JB BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578 [TBL] [Abstract][Full Text] [Related]
20. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. Kojima T; Hara H; Tsuji A; Yasui H; Muro K; Satoh T; Ogata T; Ishihara R; Goto M; Baba H; Nishina T; Han S; Sakata T; Yatsuzuka N; Doi T; Kato K Esophagus; 2022 Oct; 19(4):683-692. PubMed ID: 35668304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]